Mobile

A Multi-Center, Randomized, Double Blind, Placebo-Controlled, ‘add-on’ study to investigate the efficacy and safety of 24 weeks intravenous treatment with QAX576 in patients (≥18-75 years) with persis...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-011590-32

A Multi-Center, Randomized, Double Blind, Placebo-Controlled, ‘add-on’ study to investigate the efficacy and safety of 24 weeks intravenous treatment with QAX576 in patients (≥18-75 years) with persistent asthma not adequately controlled with inhaled corticosteroids and long acting β2-agonists

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Assess the efficacy of QAX576compared to placebo when added to existing asthma therapy with respect to the Asthma Control Questionnaire (ACQ) score following 24 weeks treatment in patients with inadequately controlled moderate to severe persistent asthma. Inadequate control is defined as an ACQ score of >1.5 at the end of the screening period (Juniper et al, 2006).

Critère d'inclusion

  • persistent moderate to severe asthma patients not adequately controlled with inhaled corticosteroids and long acting β2-agonists

Liens